Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally... This nonrandomized trial evaluates the treatment outcomes and safety of pembrolizumab plus concurrent chemoradiation therapy in stage III non–small cell lung cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Loading next page...
 
/lp/american-medical-association/pembrolizumab-plus-concurrent-chemoradiation-therapy-in-patients-with-dzURxfz0iI

References (68)

Publisher
American Medical Association
Copyright
Copyright 2021 Jabbour SK et al. JAMA Oncology.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2021.2301
Publisher site
See Article on Publisher Site

Abstract

This nonrandomized trial evaluates the treatment outcomes and safety of pembrolizumab plus concurrent chemoradiation therapy in stage III non–small cell lung cancer.

Journal

JAMA OncologyAmerican Medical Association

Published: Sep 4, 2021

There are no references for this article.